An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).

被引：0
作者：
Dirix, L.
Canon, J. L.
Amadori, D.
Villa, E.
Aldrighetti, D.
Machiels, J. P.
Verkh, L.
Bouko, Y.
Kem, K.
Giorgetti, C.
Cardoso, F.
机构：
[1] AZ ST Augustinus, Antwerp, Belgium
[2] Grand Hop Charleroi, Charleroi, Belgium
[3] IRST, Meldola, Italy
[4] San Raffaele, Milan, Italy
[5] Univ Catholique Louvain, B-1200 Brussels, Belgium
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, Milan, Italy
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：852S / 853S
页数：2
相关论文
共 50 条
[21]   Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison [J].
Stefania Redana ;
Michela Donadio ;
Franco Nolè ;
Maria Elena Jacomuzzi ;
Alessandra Beano ;
Rossella Martinello ;
Anna Sapino ;
Giuseppe Viale ;
Massimo Aglietta ;
Filippo Montemurro .
BMC Cancer, 10
[22]   First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer [J].
Xie, Hui ;
Li, Wei ;
Yao, Yufeng ;
Ni, Sujie ;
Yi, Tongbo ;
Cheng, Jinling ;
Fang, Qi ;
Zhang, Lei ;
Zhou, Jun ;
Wu, Xiaohong ;
Wang, Chunbin ;
Zhang, Yanan ;
Qin, Jianwei ;
Shao, Qing ;
Zhao, Tao ;
Huang, Xiaohong ;
Xu, Lingyun .
CANCER RESEARCH, 2022, 82 (04)
[23]   Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients [J].
Del Mastro, Lucia ;
Lambertini, Matteo ;
Bighin, Claudia ;
Levaggi, Alessia ;
D'Alonzo, Alessia ;
Giraudi, Sara ;
Pronzato, Paolo .
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) :1391-1405
[24]   Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group [J].
Inoue, Kenichi ;
Nakagami, Kazuhiko ;
Mizutani, Mitsuhiro ;
Hozumi, Yasuo ;
Fujiwara, Yasuhiro ;
Masuda, Norikazu ;
Tsukamoto, Fumine ;
Saito, Mitsue ;
Miura, Shigeto ;
Eguchi, Kenji ;
Shinkai, Tetsu ;
Ando, Masashi ;
Watanabe, Toru ;
Masuda, Noriyuki ;
Ohashi, Yasuo ;
Sano, Muneaki ;
Noguchi, Shinzaburo .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :127-136
[25]   Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group [J].
Kenichi Inoue ;
Kazuhiko Nakagami ;
Mitsuhiro Mizutani ;
Yasuo Hozumi ;
Yasuhiro Fujiwara ;
Norikazu Masuda ;
Fumine Tsukamoto ;
Mitsue Saito ;
Shigeto Miura ;
Kenji Eguchi ;
Tetsu Shinkai ;
Masashi Ando ;
Toru Watanabe ;
Noriyuki Masuda ;
Yasuo Ohashi ;
Muneaki Sano ;
Shinzaburo Noguchi .
Breast Cancer Research and Treatment, 2010, 119 :127-136
[26]   SURVIVAL OF PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER (ABC) NOT CONTINUING TRASTUZUMAB (T) BEYOND DISEASE PROGRESSION AFTER DOCETAXEL (D) AND TRASTUZUMAB [J].
Montemurro, Filippo ;
Faggiuolo, Roberto ;
Donadio, Michela ;
Redana, Stefania ;
Minischetti, Monica ;
Durando, Antonio ;
Buosi, Roberta ;
Vietti-Ramus, Guido ;
Aglietta, Massimo .
ANNALS OF ONCOLOGY, 2004, 15 :27-27
[27]   Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status [J].
Goncalves, Anthony ;
Deblock, Mathilde ;
Esterni, Benjamin ;
Tarpin, Carole ;
Bertucci, Francois ;
Gilabert, Marine ;
Charafe-Jauffret, Emmanuelle ;
Jacquemier, Jocelyne ;
Houvenaeghel, Gilles ;
Extra, Jean-Marc ;
Viens, Patrice .
ANTI-CANCER DRUGS, 2009, 20 (10) :946-952
[28]   Chemotherapy plus HER2-targeted therapy versus endocrine therapy plus HER2-targeted therapy as first-line treatment in patients with HR+/HER2+advanced breast cancer: A real-world trial [J].
Liang, Yuehua ;
Li, Hui Ping ;
Yun, Zehui .
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[29]   Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer [J].
Crown, J. ;
Kennedy, M. J. ;
Tresca, P. ;
Marty, M. ;
Espie, M. ;
Burris, H. A. ;
DeSilvio, M. ;
Lau, M. R. ;
Kothari, D. ;
Koch, K. M. ;
Dieras, V. .
ANNALS OF ONCOLOGY, 2013, 24 (08) :2005-2011
[30]   Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer [J].
Fadi Farhat ;
Joseph G. Kattan ;
Marwan Ghosn .
Cancer Chemotherapy and Pharmacology, 2016, 77 :1069-1077
12345